Ultralife Corporation ULBI
6.16
0.26
4.41%
as of 25 Sep
- Market cap
- $100.8M
- P/E
- 0.0×
Follow ULBI
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (4.83%) | (6.17%) | (4.46%) | 1.26% |
+8 more TTM periods Free account |
|
| (3.00%) | (3.70%) | (2.70%) | 0.87% | ||
ROIC |
(3.05%) | (3.53%) | (2.16%) | 2.16% | |
Return on Tangible Assets |
(5.99%) | (7.66%) | (5.42%) | 1.60% | |
Average Days of Receivables |
67.78 | 66.89 | 64.82 | 60.52 | |
Free Cash Flow per Share |
0.12 | 0.37 | 0.43 | 0.54 | |
Free Cash Flow |
2.03 | 6.13 | 7.12 | 8.95 | |
Capital Expenditures |
(3.10) | (3.75) | (3.87) | (3.60) | |
Piotroski F-Score |
3.00 | 3.00 | 4.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
2.79% | 5.30% | 5.81% | 6.37% | |
Accounts Receivable Turnover |
5.58 | 5.33 | 6.04 | 6.36 | |
Accounts Payable Turnover |
7.53 | 7.10 | 9.19 | 10.58 | |
Inventory Turnover |
2.59 | 2.75 | 2.75 | 2.94 | |
Average Days of Payables |
58.26 | 60.78 | 43.82 | 36.42 | |
Days of Inventory on Hand |
151.44 | 144.73 | 135.82 | 135.61 | |
Tax Rate |
(0.31) | (0.28) | (0.29) | (0.25) | |
Research and Development Expense of Revenue |
6.34% | 5.83% | 5.44% | 5.36% | |
Selling, General and Administrative Expense of Revenue |
15.99% | 15.84% | 15.35% | 15.22% | |
Share Based Compensation of Revenue |
0.30% | 0.38% | 0.49% | 0.49% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.78) | (1.20) | (1.86) | 7.30 | |
Depreciation/Fixed assets |
0.14 | 0.14 | 0.14 | 0.14 | |
Capex/Depreciation |
(0.55) | (0.65) | (0.67) | (0.64) | |
Revenue per Share |
11.24 | 11.28 | 11.49 | 11.21 | |
Operating CF per Share |
0.31 | 0.59 | 0.66 | 0.75 | |
Capex per Share |
(0.19) | (0.22) | (0.23) | (0.22) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Net Profit Margin |
(3.50%) | (4.37%) | (3.09%) | 0.92% |
Columns are period end dates